Massive Real-World study tracks diabetes Drug's dual benefits

NCT ID NCT05970237

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will follow 9,000 people with type 2 diabetes and high blood pressure who are already taking dapagliflozin. Researchers want to see how well the drug controls blood sugar and blood pressure in real-life settings. It is an observational study, meaning no new treatment is given—just careful tracking of outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dapagliflozin

What this could lead to

If successful, this study could provide real-world evidence on how well dapagliflozin controls blood sugar and blood pressure in everyday patients.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new treatment, only observes existing use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus hypertensive disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Gachon University Gil Medical Center

    RECRUITING

    Incheon, Namdong-gu, 21565, South Korea

    Contact